Clinical trial
Subcutaneous Amifostine Safety Study
NCT00158041 · Mt. Sinai Medical Center, Miami, Other · Completed
Key facts
| NCT number | NCT00158041 |
|---|---|
| Title | Subcutaneous Amifostine Safety Study |
| Official title | Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities |
| Lead sponsor | Mt. Sinai Medical Center, Miami, Other |
| Collaborators | MedImmune LLC Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Lung Cancer, Lymphoma |
| Intervention type | Drug |
| Interventions | Amifostine administered subcutaneously |
| Enrollment | 452 |
| Start date | Jan 1, 2002 |
| Completion | Jan 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 12, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: